Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

93.08 +0.77 (+0.83%)
Official Closing Price Updated: 7:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,802,002
Open 92.28
Bid (Size) 93.02 (1)
Ask (Size) 93.08 (6)
Prev. Close 92.31
Today's Range 91.75 - 93.11
52wk Range 15.32 - 94.92
Shares Outstanding 2,531,374,696
Dividend Yield 2.79%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dow Extends Win Streak; Wall Street Bets on Inflation's Peak
Stocks rose once again on Thursday, as investors sought value on speculation that inflation has reached its peak. 
Via Talk Markets
Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients
 
Via Benzinga

Performance

YTD
+21.09%
+21.09%
1 Month
+10.27%
+10.27%
3 Month
+21.96%
+21.96%
6 Month
+17.58%
+17.58%
1 Year
+22.60%
+22.60%

More News

Read More
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Via Benzinga
Merck Announces Third-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
CHMP Supports Approval Of Merck's Keytruda As Adjuvant In Post Surgery Melanoma Setting
Via Benzinga
Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
Via Benzinga
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
From Merck & Co., Inc.
Via Business Wire
7 Blue-Chip Stocks With Dividends to Buy Before June
Via InvestorPlace
S&P 500 1Q22 Earnings Recap: Growth Holding Up
Via Talk Markets
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
Via Benzinga
7 Quality Dividend Stocks to Buy on the Dip
Via InvestorPlace
7 Retirement Stocks to Buy for Any Market Conditions
Via InvestorPlace
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Oncocyte Reports That Its First-Of-Its-Kind DetermaCNI Blood Test That Tracks Cancer Treatment Progress Could Hit Market By 2023
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
Via Investor's Business Daily
7 Dividend Stocks to Boost Your Retirement Savings
Via InvestorPlace
Merck & Co Whale Trades For May 18
Via Benzinga
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Via Investor's Business Daily
CNBC's Final Trades: Low Volatility ETF, Kinder Morgan And This Pharma Major
Via Benzinga
4 Stocks Moved By Traders On 'Fast Money: Halftime Report'
Via Benzinga
7 Retirement Stocks for Steady Long-Term Income Growth
Via InvestorPlace
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
Stocks Are Undervalued
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.